Replies to post #215189 on Biotech Values

[BottomBounce]

$HTBX Granted Meeting with FDA to Discuss a Treatment for Non-Small Cell #LungCancer = http://ir.heatbio.com/press-releases/detail/573

[DewDiligence]

RVNC—Sell–side analysts are doing harm, IMO, by pushing so hard on 24-week duration, which is setting an unduly high bar by the pending SAKURA-1/2 data release.

What these analysts should be saying is that a purer, safer, more modern toxin that lasts somewhat longer than Botox will be a big-selling global product.